Linbid
Generic Name
Linagliptin
Manufacturer
Unimed Unihealth Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| linbid 400 mg tablet | ৳ 55.00 | ৳ 550.00 |
| linbid 600 mg tablet | ৳ 70.00 | ৳ 700.00 |
| linbid 100 mg suspension | ৳ 265.00 | N/A |
Description
Overview of the medicine
Linagliptin (Linbid) is an oral antidiabetic drug used to improve glycemic control in adults with type 2 diabetes mellitus. It works by inhibiting the enzyme dipeptidyl peptidase-4 (DPP-4).
Uses & Indications
Dosage
Adults
5 mg orally once daily.
Elderly
No dose adjustment is required.
Renal_impairment
No dose adjustment is required in patients with renal impairment.
How to Take
Take Linbid orally once daily, with or without food. Swallow the tablet whole with water.
Mechanism of Action
Linagliptin inhibits the enzyme dipeptidyl peptidase-4 (DPP-4), which degrades incretin hormones like Glucagon-Like Peptide-1 (GLP-1) and Glucose-dependent Insulinotropic Polypeptide (GIP). By inhibiting DPP-4, Linagliptin increases the active concentrations of these incretin hormones, leading to enhanced glucose-dependent insulin secretion and suppressed glucagon secretion, thus lowering blood glucose levels.
Pharmacokinetics
Onset
Significant DPP-4 inhibition observed within 24 hours. Steady-state plasma concentrations are achieved within 3 days.
Excretion
Primarily excreted via the enterohepatic pathway (bile/feces, approximately 80%). A small portion (approximately 5%) is excreted unchanged in urine.
Half life
Terminal elimination half-life is long (>100 hours), but the effective half-life for DPP-4 inhibition is approximately 12 hours.
Absorption
Rapidly absorbed after oral administration. Absolute bioavailability is approximately 30%. Peak plasma concentrations (Tmax) are reached within 1.5 hours.
Metabolism
Minor metabolism occurs; the main pathway is cyclization to form an inactive metabolite. CYP enzymes play a minimal role.
Side Effects
Contraindications
- •History of serious hypersensitivity reaction to linagliptin (e.g., anaphylaxis, angioedema, exfoliative skin conditions).
- •Not indicated for use in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.
Drug Interactions
Rifampicin
Coadministration with rifampicin (a P-glycoprotein/CYP3A4 inducer) significantly decreases linagliptin exposure, potentially reducing efficacy. Dose adjustment typically not required but monitor glycemic control.
P-glycoprotein inhibitors (e.g., Ritonavir)
May increase linagliptin exposure, but generally not clinically significant. No dose adjustment needed.
Storage
Store below 30°C (86°F). Protect from light and moisture. Keep out of reach of children.
Overdose
In the event of an overdose, discontinue treatment and initiate appropriate symptomatic and supportive measures. Linagliptin is not effectively removed by hemodialysis or peritoneal dialysis.
Pregnancy & Lactation
Pregnancy: Category B. Limited data on human pregnancy. Use only if the potential benefit justifies the potential risk to the fetus. Lactation: Unknown if excreted in human milk. Caution should be exercised when administered to a nursing woman.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
24 to 36 months from manufacturing date, depending on specific formulation.
Availability
Available in pharmacies
Approval Status
Approved by major regulatory bodies (e.g., FDA, DGDA)
Patent Status
Patented, but generics available in some markets
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in
